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STAMPEDE is a multi-arm multi-stage randomised controlled trial protocol, recruiting men with locally 
advanced or metastatic prostate cancer who are commencing long-term androgen deprivation therapy. 
Opening to recruitment with five research questions in 2005 and adding in a further five questions over the 
past six years, it has reported survival data on six of these ten RCT questions over the past two years. [1-3] 
Some of these results have been of practice-changing magnitude, [4, 5] but, in conversation, we have 
noticed some misinterpretation, both over-interpretation and under-interpretation, of subgroup analyses by 
the wider clinical community which could impact negatively on practice. We suspect, therefore, that such 
problems in interpretation may be common. Our intention here is to provide comment on interpretation of 
subgroup analysis in general using examples from STAMPEDE. Specifically we would like to highlight some 
possible implications from the misinterpretation of subgroups and how these might be avoided, particularly 
where these contravene the very design of the research question. In this, we would hope to contribute to the 
conversation on subgroup analyses. [6-11] 
For each comparison in STAMPEDE, or indeed virtually any trial, the interest is the effect of the research 
treatment under investigation on the primary outcome measure across the whole population. Upon reporting 
the primary outcome measure, the consistency of effect across pre-specified subgroups, including 
stratification factors at randomisation, is presented; these are planned analyses.  
The forest plot is a valuable tool in displaying and assessing treatment effects in subgroups. Forest plots, 
first used in 1978, were initially used for illustration (in meta-analyses) of the treatment effect within studies, 
offering a sense of consistency of effect across studies. [12, 13] The lack of consistency, or heterogeneity, is 
formally calculated and taken into consideration when interpreting the pooled estimate. Forest plots 
traditionally offer two distinct vertical lines for reference: no effect (e.g. hazard ratio (HR)=1.00) and the 
estimated, overall treatment effect. The line of no effect is an important consideration in assessing the overall 
treatment effect: the confidence interval for any one of the trials may cross this line if it is underpowered or it 
observed no effect on the outcome of interest, and, for each well-powered study on the forest plot, the 
confidence intervals should be fairly narrow. This line of no effect also helps in the interpretation of the 
overall, pooled effect. The second line presents the pooled effect and helps readers to consider how each 
individual study looks compared to this overall effect. 
Illustration of treatment effect across subgroups within one trial is a more recent use of forest plots, and in 
this scenario the emphasis must undoubtedly be placed on the consistency of treatment effect, not the 
individual effect within each subgroup. Unlike the individual trials in a meta-analysis of trials, each subgroup 
within one trial, usually, will not be well-powered at the time of reporting the overall effect and the 
confidence intervals will, typically, be wide as a result. Therefore, any assessment based solely on whether 
confidence intervals for treatment effect within a subgroup cross the line of no effect, are unhelpful and 
potentially harmful. This is particularly the case where an interaction has been tested for and there is no 
evidence to suggest there is indeed any difference in the overall treatment effect.  
From the STAMPEDE perspective, we consider this to be an important distinction, specifically in relation to 
the translation in to practice of trial results found to show overwhelming benefit in the entire, eligible trial 
population. Most notably this has been most apparent in relation to the subgroup of metastatic status at 
randomisation. Patients with metastatic disease (M1) at randomisation have substantially poorer prognosis 
and therefore, sadly, contribute the higher proportion of events sooner; conversely those patients with 
non-metastatic disease (M0) at randomisation live longer and as such, subgroup analyses on survival at the 
time of first reporting can always be expected to appear relatively immature. For reported survival results 
relating to both the “docetaxel comparison” and the “abiraterone comparison”, we observed no evidence of 
inconsistency in the treatment effect across both subgroups of metastatic status at randomisation, with a 
compelling overall effect and the hazard ratio (HR) in each group pulling in the direction favouring the 
research treatment over the standard-of-care; there was no evidence of a lack-of-consistency by metastatic 
status for either additional treatment in survival nor failure-free survival. [1, 3] 
The focus of commenters on both the “docetaxel comparison” and the “abiraterone comparison” from 
STAMPEDE has most often been on the beneficial effect in the M1 subgroup, despite the underlying design 
and results being positive for the broader population. 
Figure 1 shows three example subgroup analyses from the “abiraterone comparison” in STAMPEDE on 
overall survival, one already published [3] and two deliberately trawled for. The first section of the forest plot 
shows the subgroup analysis by metastatic status at randomisation. The interaction p-value of 0.37 shows no 
good evidence of heterogeneity of treatment effect across these subgroups. There is more evidence at this 
time in the M1 setting so the confidence intervals are narrower than for M0 but one should take the overall 
effect from the trial; the point estimate in the M0 setting (HR=0.75) is exactly that targeted by the protocol. 
However, many in the clinical community, and some commissioners in the case of docetaxel, have only 
focused on the data from the M1 subgroup.  
The second part of Figure 1 shows the impact on survival of abiraterone based on day of birth. The 
confidence intervals are broad because the patients are split, fairly evenly, into 7 groups. Like with metastatic 
status, there is no good evidence of heterogeneity (p=0.33). There is no reasonable clinical hypothesis to 
underpin a different outcome by day of birth. Therefore, the fact that the point estimates vary by weekday of 
birth must be by chance. Yet, some of the confidence intervals include the null line and some do not. Under 
reducto ad absurdum, people uncertain about the impact of abiraterone in M0 patients based on the first part 
of the graph should also be uncertain about the addition of abiraterone in patients who were born during the 
latter part of the week (Thursday to Sunday); after all, their confidence intervals also all include the null line 
e.g. Thursday’s HR=0.69 with 95%CI 0.42 to 1.15.  
However, we should also be cautious not to over-interpret subgroups. The final part of Figure 1 is based on 
weekday of diagnosis, where the point estimate of abiraterone is less favourable for people diagnosed on a 
Monday than those on other days with striking evidence of heterogeneity (p=0.021). There is no reasonable 
clinical rationale in a multi-centre multinational clinical trial for this, and even with apparent statistical 
evidence, this must be a chance finding (note: it is a chance finding – we trawled through implausible 
subgroups before deliberately selecting this one). 
Estimation of treatment effect within specific subgroups can of course be desirable, and stratification is the 
crucial step in moving forward towards “personalised” medicine.  
In summary, it is important to consider the reasons behind low event rates and whether these are 
independent of a treatment effect. For this example, the M0 subgroup is prognostically favourable and does 
better regardless of adding in the research treatment. However, this does not equate to there being no 
treatment effect; the evidence here is consistent across both populations. There are clearly circumstances in 
which over-interpretation of subgroups can be detrimental and access to treatments is arguably one of these. 
Moving forward we would provide the following recommendations when interpreting trial results: 
 Focus should be placed on the design of the trial; what is the primary hypothesis being tested? 
 When considering any difference in treatment effect across subgroups the primary assessment 
should be relative to the direction of overall effect and whether the subgroup effect contests this i.e. 
is there consistency across subgroups?  
 Context can help: consider whether the treatment effect is consistent across other trial endpoints. 
 Where there is inconsistency the clinical plausibility of this should be clearly considered. 
Context is particularly helpful for the “abiraterone comparison” in STAMPEDE. The impact on failure-free 
survival, the intermediate primary outcome measure for the trial, is very positive for adding abiraterone 
across the board and positive in each of the subgroups by baseline metastatic status (Figure 2). There is 
some evidence of heterogeneity of the treatment effect in these groups (p=0.085) which is more favourable 
in the M0 setting than in the M1 setting. Commentators who take that there is an impact on survival in M1 
disease but not M0 must also conclude that there is a larger impact on FFS in the M0 setting.  
In conclusion, readers must protect themselves equally from over-interpretation and under-interpretation of 
subgroup effects. The onus on interpretation of results subgroup analyses lies equally with the journal and 







1. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line 
long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, 
multiarm, multistage, platform randomised controlled trial. The Lancet 387: 1163-1177. 
2. Mason MD, Clarke NW, James ND et al. Adding Celecoxib With or Without Zoledronic Acid for 
Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, 
Multistage, Platform, Randomized Controlled Trial. Journal of Clinical Oncology 2017; 35: 1530-1541. 
3. James ND, de Bono JS, Spears MR et al. Abiraterone for Prostate Cancer Not Previously Treated with 
Hormone Therapy. New England Journal of Medicine 2017. 
4. England N. Clinical Commissioning Policy Statement: Docetaxel in combination with androgen 
deprivation therapy for the treatment of hormone naïve metastatic prostate cancer. 2016. 
5. NICE. Hormone-sensitive metastatic prostate cancer: docetaxel. 2016. 
6. Fletcher J. Subgroup analyses: how to avoid being misled. British Medical Journal 2007; 335: 96 
7. Naggara O, Raymond J, Guilbert F, Altman DG. The Problem of Subgroup Analyses: An Example from 
a Trial on Ruptured Intracranial Aneurysms. American Journal of Neuroradiololgy 2011; 32: 633-36 
8. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in 
subgroups of patients in randomised clinical trials. JAMA 1991;266:93-8. 
9. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: a survey of three 
medical journals. N Engl J Med 1987;317:426–32 
10. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78–84 
11. Schulz KF, Grimes DA. Multiplicity in randomised trials. II. Subgroup and interim analyses. Lancet 
2005;365:1657–61 
12. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The Importance of Beta, the Type II Error and Sample 
Size in the Design and Interpretation of the Randomized Control Trial. New England Journal of 
Medicine 1978; 299: 690-694. 
13. Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. British Medical Journal 2001; 
322: 1479-1480. 
  
Figure 1: Forest plot from STAMPEDE data showing the effect on survival of adding abiraterone to 
SOC, within subgroups 
 
  
Figure 2: Scatter plot of the treatment effect of abiraterone on survival and failure-free survival by 
baseline metastatic status 
 
